GlassScriptPhysician profile
Siavash Sobhani
NPI 1790872455
$4,741.15
in general payments reported to CMS, 2019-2025
30 companies · $589 in 2025
The $589 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $446 · 2021: $811 · 2022: $727 · 2023: $634 · 2024: $787 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,214.98 | 2019-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,137.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $342.42 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $265.81 | 2019-2024 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $255.91 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $191.74 | 2019-2023 | Xarelto |
| Pfizer INC. | $162.63 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.10 | 2023-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $135.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $115.71 | 2019-2020 | |
| Daiichi Sankyo INC. | $95.43 | 2024-2025 | Injectafer |
| Sanofi-Aventis U.S. LLC | $88.52 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $77.27 | 2024 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $75.02 | 2019-2021 | |
| Genentech USA, INC. | $60.60 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $53.86 | 2020-2022 | |
| Amarin Pharma, INC. | $44.30 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $40.27 | 2025 | Recorlev, Gvoke Hypopen |
| Genzyme Corporation | $36.71 | 2023 | |
| Allergan, INC. | $34.65 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.06 | 2022 | |
| Exact Sciences Corporation | $20.44 | 2024 | Cologuard Collection Kit |
| Endo Pharmaceuticals INC. | $20.40 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.69 | 2023 | Rexulti |
| Scynexis, INC. | $17.46 | 2021 | |
| Boston Scientific Corporation | $17.35 | 2019 | |
| Ardelyx, INC. | $16.27 | 2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $15.05 | 2020 | |
| Abbott Laboratories | $14.00 | 2023 | Freestyle Libre 3 |
| Hikma Pharmaceuticals USA | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siavash Sobhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.